Across TCGA pan-cancer cohorts, SPRED2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SPRED2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPRED2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPRED2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD and LSCC are the cancer types where SPRED2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.892	0.275	.024	6	view →
LSCC	DFS	Median	All	0.374	0.976	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: SPRED2 tumor-vs-normal RNA expression · all SPRED2 data types